AMP German Cannabis Group Inc. and Aphria Inc.’s wholly-owned German subsidiary, CC Pharma GmbH, have entered into a strategic agreement covering joint marketing of sales for Aphria brand medical cannabis products for the German market. The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany. In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.
Hendrik Knopp, Managing Director of Aphria Germany GmbH mentioned, “We are proud to launch our high-quality medical cannabis under the Aphria brand in Germany with the support of AMP. This agreement provides the opportunity to expand the Aphria brand in Germany, one of our key international markets.”
Dr. Stefan Feuerstein, Director and President of AMP, commented, “We are proud to partner with Aphria and CC Pharma GmbH. Our sole focus is to sell medical cannabis in Germany, which makes us an ideal partner to co-promote and sell the Aphria brand. In preparation for this partnership, we have significantly expanded our sales team to sell the Aphria and AMP brands as well as other branded medical cannabis products across Germany.”
Headquartered in Leamington, Ontario, Aphria cultivates, processes, markets and sells medical and adult-use cannabis, cannabis-derived extracts and derivative cannabis products in Canada under the provisions of the Cannabis Act and globally pursuant to applicable international regulations. Aphria also manufactures, markets and sells alcoholic beverages in the United States. For more information, please visit: https://aphria.ca.
Founded in 1999, CC Pharma is based in Densborn, Germany and is one of the leading national distributors of pharmaceutical products to pharmacists in Germany, with over 13,000 pharmacies in its sales network. For more information, please visit: www.cc-pharma.de.
AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis from Europe and elsewhere into Germany. AMP sources, stores, transports, delivers, and sells medical cannabis products to pharmaceutical distributors or pharmacists directly, the only point-of-sale for medical cannabis to German patients with a physician’s prescription. AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany.